For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

16th Dec 15

Bronchitol Paediatric Cystic Fibrosis Clinical Trial Reports Positive Results

Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.

Read full media release - pdf
15th Dec 15

Pharmaxis in the News - 15 December 2015

Bennelong Innovation Forum

Bennelong GPPharmaxis CEO Gary Phillips was a key speaker at the inaugural Bennelong Innovation Forum attended by the Minister for Health, Sussan Ley, at Macquarie University on 9 December.

Gary told an audience of more than 400 attendees how Pharmaxis has grown through innovation and partnering.

The Australian

Pharmaxis CEO Gary Phillips speaks to The Australian about policy to support the commercialisation of biomedical research.

Read full media release - pdf
6th Oct 15

Pharmaxis in the News - 6 October 2015

Following Pharmaxis recent announcement of a successful phase 1 clinical trial of the drug it sold to Boehringer Ingelheim earlier this year, Pharmaxis chief executive officer Gary Phillips has been interviewed by several journalists and analysts. Those interviews currently available on the internet may be accessed from the following links.

Australian Financial Review (article):

”Pharmaxis has a new business model – is it now the least risky biotech stock?”

 ABC Online (article & interview):

“Valley of death' journey for Australian biotech to pharmacy shelves”

CEO Gary Phillips discusses the renewal at Pharmaxis and drug development in Australian with ABC The Business.

CommSec TV - Executive Series

Published on 4 Oct 2015

CommSec’s Tom Piotrowski speaks with Pharmaxis Limited (PXS) CEO, Gary Phillips about the company’s successful Phase 1 trial results for a drug which it has sold to Germany’s Boehringer Ingelheim.

Proactive Investors (interview):

Pharmaxis' CEO Gary Phillips talks clinical trials and Boehringer deal with Proactive Investors

Bioshares article published 25 September 2015:

Pharmaxis Explains Different Approaches To NASH, Adds More Detail To BI Deal

Biotech Daily

Pharmaxis, Boehringer PXS4728A Meets Phase I Endpoints

Read also Pharmaxis latest Corporate Summary

Read full media release - pdf